Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
about
Molecular biology of lung cancerNon-small cell lung cancer: current treatment and future advancesRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCGene aberrations for precision medicine against lung adenocarcinomaRAS-MAPK pathway epigenetic activation in cancer: miRNAs in actionDifferences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese populationUsing large-scale genomics data to identify driver mutations in lung cancer: methods and challengesThe Utilization of Cytologic Fine-Needle Aspirates of Lung Cancer for Molecular Diagnostic TestingSystemic and targeted therapies for early-stage lung cancerReview of the current targeted therapies for non-small-cell lung cancerTargeted therapies in development for non-small cell lung cancerRole of molecular studies in the diagnosis of lung adenocarcinomaMutation of the BRAF genes in non-small cell lung cancerMolecular pathology of non-small cell lung cancer: a practical guide.Molecular pathology of lung cancer: key to personalized medicine.Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.Liquid biopsy in early stage lung cancerTargeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALKImmunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastasesCommon Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never SmokersCharacteristics of lung cancers harboring NRAS mutationsAllele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutationLung cancer in womenBRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencingBeyond histology: translating tumor genotypes into clinically effective targeted therapies.Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathwayA meta-analysis of the association between BRAF mutation and nonsmall cell lung cancerCoexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.Molecular pathways and therapeutic targets in lung cancerMolecular Testing of Lung CancersReview of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice.New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapyBRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis.Rapid onset lung squamous cell carcinoma with prominent peritoneal carcinomatosis and an eosinophilic leukemoid reaction, with coexistence of the BRAF V600E and oncogenic KRAS G12A mutations: A case report.Racial disparity in metabolic regulation of cancer.Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's PerspectiveUsage patterns of biomarkers in non-small-cell lung cancer patients in India: Findings from a systematic review and survey.
P2860
Q24606677-C10B0F96-7572-44AF-97B0-A9403016E401Q26740333-0B4B83D6-BF4C-46FC-9FD2-EB82BE1E401AQ26747276-961DBC0F-1C92-4EB8-B589-283DA53721DAQ26749348-EC3BF15C-5C25-44E7-867E-E9C4E9394F8EQ26773479-FB3D7FAA-DEF0-4EE2-927F-121F795D9543Q26786594-A8704764-E082-4304-A22F-91A19A0901BDQ26800833-A342715F-F54E-4A3E-BBCD-42FE1B82055DQ26824315-89F824C8-B077-4018-9B61-82B0B2CD737EQ26865490-9F07593D-5C59-4A73-B1E7-C4DACE1F0070Q27015079-4C62E572-AB62-41C5-BE35-582DDE17F019Q27022852-EF67D5E0-72A3-4AA1-BC3A-BC2777D5E397Q27023212-859EF113-BFB4-4703-B7EA-3440E504DD0FQ27025345-C40FB96A-2DBE-4D4C-98DB-4D8E632BF03DQ27690919-BB4A1A6D-DA50-4C7C-A344-CC58939F67F1Q27691299-60784BEC-9FF8-4B3F-A564-0519AD3CB4BCQ27851860-678E1FDC-6E5D-45E1-8AD9-A7D42A376A3CQ27852128-791ECF18-9139-4EC3-B94E-D998A0D75088Q27853371-0703FF90-96C2-420C-9AC5-70434FC5E3FEQ28065994-758D933F-BD2A-462D-A834-964506D5D057Q28083446-C7CDD4E1-D49A-4188-8F44-E5A3E1B728D0Q28250795-71B59A27-F496-49C3-B38E-E91AD9F96207Q28394324-49C1ABD7-F25B-4433-9A33-41F45082D8D4Q28706226-42C2AEAB-8D9B-460D-98D8-24AEF6997DEAQ28730199-AF118A34-FCD7-4F47-B907-5809453AD1FFQ29248783-0DAB140C-76FC-4BC7-9DF7-8F7D327150BDQ30458424-31950166-DD40-4761-860B-F50E3F0B4E8CQ30514084-D5EC4973-8334-4E83-B323-961B6A5A4012Q33560928-3B10E10A-3F95-4DD2-9984-3970F9FEE6CEQ33618711-EEFDFB99-74F1-4F73-9DD3-198EBFE18848Q33621342-74541AFB-A859-44B1-B4F0-917ACBA76731Q33682941-3C87A2ED-73FE-4ED2-897F-B607E7E2E876Q33688872-4390CCBA-CBC0-44EA-A04F-0A557ED3B425Q33729715-95E80541-65D1-4E3B-8C87-159387E852EAQ33757138-A1C7DD84-3D30-41DA-9F5C-76BE9DF48A23Q33824552-89164BE2-D1F2-409C-8D50-9009D856269BQ33826001-9CCAE328-8ED6-49CF-8FC0-0CE8F6C495ACQ33843962-945B4752-714C-4DC2-8D01-03B1F38CDD4CQ33906704-7457866F-9DB6-42FD-8592-7D5A06CCDB46Q33906921-8BD60F55-925C-40D7-ADEF-9A8BEBDBD927Q34031517-D7AC14ED-7703-464B-96D1-7FDA75EC2D29
P2860
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
@ast
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
@en
type
label
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
@ast
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
@en
prefLabel
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
@ast
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
@en
P2093
P2860
P356
P1476
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
@en
P2093
Camelia S Sima
Gregory J Riely
Maria E Arcila
Mark G Kris
Michael Fara
Paul K Paik
Vincent A Miller
P2860
P304
P356
10.1200/JCO.2010.33.1280
P407
P50
P577
2011-04-11T00:00:00Z